Results 101 to 110 of about 51,507 (268)

Association Between Preoperative Dyslipidemia and the Prognosis of Patients With Endometrial Cancer: A Retrospective Cohort Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Endometrial cancer (EC) is closely related to metabolic disorders. We aimed to investigate whether preoperative dyslipidemia independently affects the prognosis of patients with EC. One hundred and ninety‐four women diagnosed with EC by pathology and who had undergone standardized surgical treatment at the Affiliated Hospital of Jining Medical
Song Li, Rong‐He Sun, Qing Chen, Zeng‐Shu Huang, Yun‐Fei Wang, Chang‐Zhong Li   +5 more
wiley   +1 more source

Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors

Cancer Treatment and Research Communications
Breast cancer is a leading cause of death among women globally. Estrogen receptor (ER)-positive breast cancers account for ∼70 % of breast cancer diagnoses worldwide. Endocrine therapy is the primary treatment approach for ER-positive breast cancer.
Nayoung Kim, Kiven Erique Lukong
doaj   +1 more source

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

Med Research, EarlyView.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang, Diyuan Zhang, Yuqin Zhou, Ling Qian, Yan Wang, Lei Peng, Min Zhao, Hao Tian, Zhenyu Wu, Aiqi Tang, Minghao Sun, Yi Zhang, Xiaowei Qi   +12 more
wiley   +1 more source

Aromatase inhibitors in post-menopausal endometriosis

Reproductive Biology and Endocrinology, 2011
Postmenopausal endometriosis is a rare clinical condition. The diagnosis and treatment of an endometriotic lesion in postmenopausal women is complicated.
Devroey Paul, Velasco Juan-Garcia, Kyrou Dimitra, Grimbizis Grigoris, Zavos Apostolos, Fatemi Human M, Polyzos Nikolaos P, Tarlatzis Basil, Papanikolaou Evangelos G   +8 more
doaj   +1 more source

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors [PDF]

, 2014
Background: Recent data have raised concern about the clinical efficacy of aromatase inhibitors in overweight and/or obese breast cancer patients. We report in vivo aromatase inhibition and plasma and tissue oestrogen levels in relation to body mass ...
Dowsett, Mitch, Haynes, Benjamin P., Lønning, Per Eystein   +2 more
core  

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources

Increased expression of aromatase after focal cerebral ischemia: Relevance to neuroprotection and functional recovery

Neuroprotection, EarlyView.
Abstract Aim Aromatase is the key enzyme in the biosynthesis of 17β‐estradiol, the most potent estrogen, which has pleiotropic neuroprotective properties. Aromatase levels increase in the brain after stroke, and its gene variants increase susceptibility to stroke. This study aims to determine whether aromatase overexpression improves stroke outcome and
Lindsay Gallagher, Anna F. Dominiczak, Luis M. Garcia‐Segura, Nobuhiro Harada, J. B. Hutchison, James M. Mullin, Delyth Graham, Peter O'Shaughnessy, Hilary Victoria O. Carswell   +8 more
wiley   +1 more source

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Nature Communications, 2016
Aromatase inhibitors are used to treat oestrogen receptor positive breast cancers but the molecular basis for the response of patients is unclear. Here, the authors use samples from an aromatase inhibitor clinical trial and show that tumours from poor ...
Pascal Gellert, Corrinne V. Segal, Qiong Gao, Elena López-Knowles, Lesley-Ann Martin, Andrew Dodson, Tiandao Li, Christopher A. Miller, Charles Lu, Elaine R. Mardis, Alexa Gillman, James Morden, Manuela Graf, Kally Sidhu, Abigail Evans, Michael Shere, Christopher Holcombe, Stuart A. McIntosh, Nigel Bundred, Anthony Skene, William Maxwell, John Robertson, Judith M. Bliss, Ian Smith, Mitch Dowsett, POETIC Trial Management Group and Trialists   +25 more
doaj   +1 more source

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

Precision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source

Aromatase Inhibitors for Ovulation Induction [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2015
Normogonadotropic anovulation, including polycystic ovary syndrome (PCOS), is one of the main causes of infertility. Recent meta-analysis and randomized controlled trial suggest the use of aromatase inhibitors (ie, letrozole) as effective drug and first-line treatment to restore fertility in these patients.
openaire   +3 more sources